Form 8-K - Current report:
SEC Accession No. 0001193125-25-120345
Filing Date
2025-05-15
Accepted
2025-05-15 08:41:34
Documents
14
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d106735d8k.htm   iXBRL 8-K 28926
2 EX-99.1 d106735dex991.htm EX-99.1 74433
  Complete submission text file 0001193125-25-120345.txt   233544

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20250514.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20250514_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20250514_pre.xml EX-101.PRE 10814
16 EXTRACTED XBRL INSTANCE DOCUMENT d106735d8k_htm.xml XML 3515
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 25948980
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)